Lumida
/AVBP
⌘K
Arrivent Biopharma Inc

Arrivent Biopharma Inc

AVBP
$33.19USD+1.31%+0.43 today

MARKET CAP

1.5B

P/E (TTM)

FWD P/E

DAY RANGE

$32 – $34

52W RANGE

$16
$36

AI Summary

Stalk
StalkMedium

AVBP remains in a Stage 2 advancing uptrend marked by higher highs and higher lows. After a recent pullback into the rising 9/21 EMA band and testing the 50 DMA support area, price has held without signs of exhaustion. Medium-term bias stays Bullish, but short-term execution readiness is Neutral—suggesting patience and selective engagement on pullbacks into EMA and 50 DMA support.

  • 100% Buy ratings, $44.83 average target signals 33% upside.
  • Stock gained 45% since Mar 31 on Phase 3 trial anticipation.
  • Negative earnings yield and $160.6 M net loss imply weak profitability.
Full analysis →
Insider Trades2 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 11, 2025BuyAVBPRobin LachapelleChief Operating Officer11,153$2.28$1.5B-7.37%+106.15%$25.4K+2.79%Stalk
Sep 19, 2024BuyAVBPRobin LachapelleChief Operating Officer27,566$3.28$1.5B-7.37%+106.15%$90.5K+4.33%Stalk